---
layout: post
title: "Medications for the Treatment of Opioid Use Disorder"
date: 2026-02-05 19:08:05 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-01693
original_published: 2024-02-02 00:00:00 +0000
significance: 8.00
---

# Medications for the Treatment of Opioid Use Disorder

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 02, 2024 00:00 UTC
**Document Number:** 2024-01693

## Summary

This final rule modifies and updates certain provisions of regulations related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. This includes making flexibilities put forth during the COVID-19 Public Health Emergency (PHE) permanent, as well as expanding access to care and evidence-based treatment for OUD. The final rule also removes all language and rules pertaining to the Drug Addiction and Treatment Act (DATA) Waiver from the regulations pursuant to the "Consolidated Appropriations Act, 2023".

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder)
- API: https://www.federalregister.gov/api/v1/documents/2024-01693

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
